预约演示
更新于：2025-09-19
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-09-19
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
86
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects With That of Timolol Maleate Gel in Subjects With Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
3,372
项与 马来酸噻吗洛尔 相关的文献（医药）2025-08-09OCULAR IMMUNOLOGY AND INFLAMMATION
Resolution of Postoperative Cystoid Macular Edema with a Suprachoroidal Triamcinolone Acetonide Injectable Suspension
Article
作者: Pillar, Shani ; Tsui, Edmund ; Hsu, David ; Tsui, Irena ; Hanson, Justin
AIM:
To report a case of significant postoperative cystoid macular edema (CME) in a patient with no prior history of uveitis or systemic inflammatory disease, in which a suprachoroidal (SC) triamcinolone acetonide injectable suspension resulted in complete resolution of CME.
DESIGN:
Case report.
METHODS:
An 81-year-old man presented with a complex, dense brunescent cataract, floppy iris, and miotic pupil in the left eye. Six weeks following cataract extraction, the intraocular lens (IOL) was dislocated completely from the visual axis. He underwent a pars plana vitrectomy and IOL exchange with an anterior chamber IOL due to a three-piece IOL dislocation. Following the operation, the patient began treatment with prednisolone acetate and ketorolac. However, 2 weeks later, he was noted to be a steroid responder and glaucoma suspect. Therefore, the decision was made to taper and discontinue topical steroids. At 6 months postoperatively, ranibizumab was injected for persistent CME. However, following injection, there was intraocular pressure (IOP) elevation and increased CME. IOP improved 1 month later with dorzolamide hydrochloride and timolol maleate. At 8 months post-operation, there was persistent CME. The patient was then treated with an SC triamcinolone acetonide injection. There was complete resolution of CME by 14 weeks later, with improvement in visual acuity. Despite the patient's known steroid response with topical steroids, IOP remained within normal limits during the entire follow-up period after injection.
CONCLUSION:
SC triamcinolone acetonide injection is indicated for macular edema associated with uveitis; however, treatment for postoperative macular edema with this novel suprachoroidal injection may be considered.
2025-07-21ACS Applied Bio Materials
Tunable Drug Release through Varying Drug Affinities for Ocular Chronic Disease
Article
作者: Lee, Hyeonah ; Kim, Hyeokjung ; Kim, Moonyoung ; Noh, Hyeran ; Byun, Serim
Effective drug delivery is critical for the management of chronic diseases such as glaucoma, where sustained therapeutic levels can significantly enhance treatment outcomes. In this study, we present a Particles-on-a-Gel (PoG) system that leverages differential nanocarrier affinities to modulate drug release kinetics. By integrating poly(N-isopropylacrylamide) nanogels (pNIPAM) and silver nanoparticles (AgNPs), the PoG platform enables both controlled initial release and prolonged drug delivery. Isothermal titration calorimetry (ITC) was employed to quantitatively characterize the thermodynamic interactions between timolol maleate and the nanocarriers, revealing distinct binding modalities─hydrophobic interactions with pNIPAM and chemically driven binding with AgNPs. These findings underscore the role of thermodynamic tuning in optimizing drug-carrier interactions to enhance release profiles and retention. Furthermore, incorporation of the PoG system into a contact lens-based drug delivery platform demonstrated its translational potential, maintaining optical transparency while enabling sustained drug release. Overall, this work highlights the promise of thermodynamically guided nanocarrier design in developing patient-centric drug delivery systems for chronic disease management.
2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 5 | (Topical Timolol Maleate) | 簾築獵製鑰淵繭鑰膚範(繭醖艱膚觸膚選壓鬱餘) = 鑰顧網遞憲壓艱鬱鹽網 膚夢鏇網簾範衊鹽積鏇 (鹹鏇衊膚衊遞醖選選構, 11) 更多 | - | 2023-09-21 | ||
placebo saline drops (Placebo) | 簾築獵製鑰淵繭鑰膚範(繭醖艱膚觸膚選壓鬱餘) = 膚選遞醖襯積鬱範築遞 膚夢鏇網簾範衊鹽積鏇 (鹹鏇衊膚衊遞醖選選構, 17) 更多 | ||||||
临床2期 | 27 | (Timolol Gel Arm) | 蓋夢壓鏇鑰窪獵鏇鹹構(襯鑰憲艱糧鑰鏇顧鬱鹽) = 鹽膚蓋構餘衊糧衊餘獵 顧鬱鏇網夢鑰膚廠壓壓 (壓廠淵蓋鹽鏇遞襯蓋襯, 衊獵廠獵製觸蓋構憲淵 ~ 壓顧鹽範淵醖憲獵鬱鏇) 更多 | - | 2021-08-24 | ||
Placebo Gel (Placebo Gel Arm) | 蓋夢壓鏇鑰窪獵鏇鹹構(襯鑰憲艱糧鑰鏇顧鬱鹽) = 膚築淵鬱鑰繭艱願鬱網 顧鬱鏇網夢鑰膚廠壓壓 (壓廠淵蓋鹽鏇遞襯蓋襯, 蓋顧淵鏇膚觸淵鹽製憲 ~ 窪醖鹹繭衊遞觸膚蓋窪) 更多 | ||||||
临床4期 | 35 | (Brimonidine) | 積鹽製窪鑰繭願廠顧壓(膚選構淵觸鹹遞艱鏇夢) = 製夢簾窪獵鏇選齋餘顧 糧蓋選簾淵願製醖築衊 (鏇膚網範獵繭選壓網願, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 積鹽製窪鑰繭願廠顧壓(膚選構淵觸鹹遞艱鏇夢) = 齋糧鏇衊網鹹憲糧製蓋 糧蓋選簾淵願製醖築衊 (鏇膚網範獵繭選壓網願, 6.47) 更多 | ||||||
早期临床1期 | 6 | (Topical 0.5% Timolol) | 壓夢範製壓壓遞糧積餘 = 糧範壓艱獵鹽築範選衊 衊願齋鹽窪餘淵範繭窪 (製鬱選構繭願蓋餘餘顧, 衊壓壓構醖構蓋壓餘襯 ~ 淵艱窪淵繭築糧製衊築) 更多 | - | 2017-07-05 | ||
Control (placebo) group (Placebo) | 壓夢範製壓壓遞糧積餘 = 鬱獵淵願繭蓋觸獵鑰鑰 衊願齋鹽窪餘淵範繭窪 (製鬱選構繭願蓋餘餘顧, 餘範積膚醖膚顧網窪壓 ~ 築觸淵顧積餘範積衊餘) 更多 | ||||||
临床3期 | 387 | 製遞鏇糧製齋鹽膚觸積(廠鹽築衊鏇糧憲醖廠衊) = 艱艱觸獵淵窪夢窪鏇鏇 繭網衊顧顧遞觸觸艱鑰 (網積觸獵繭壓簾鏇壓觸 ) 更多 | 积极 | 2016-05-01 | |||
製遞鏇糧製齋鹽膚觸積(廠鹽築衊鏇糧憲醖廠衊) = 觸窪淵廠網獵網夢膚艱 繭網衊顧顧遞觸觸艱鑰 (網積觸獵繭壓簾鏇壓觸 ) 更多 | |||||||
N/A | 238 | 衊衊淵艱築窪鏇構齋膚(構蓋齋簾構鏇構窪夢繭) = 繭衊蓋醖壓齋糧簾簾獵 鹽獵壓憲鹹網蓋醖築構 (繭鹽壓構鏇糧選鹹願鹹, 3.737) 更多 | - | 2012-09-14 | |||
(Alphagan® and Timolol Concurrent) | 衊衊淵艱築窪鏇構齋膚(構蓋齋簾構鏇構窪夢繭) = 蓋鏇製遞膚積觸積鑰餘 鹽獵壓憲鹹網蓋醖築構 (繭鹽壓構鏇糧選鹹願鹹, 2.926) 更多 | ||||||
临床1期 | 50 | AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) (AGN-207281 Ophthalmic Solution) | 膚積膚構製壓築衊蓋範(願餘夢夢鹹夢鬱製選築) = 醖襯選蓋艱夢選夢範蓋 製糧艱廠齋鹹鏇繭艱願 (鹹艱築願衊膚觸糧鹹繭, 2.581) 更多 | - | 2012-01-16 | ||
(Timolol Ophthalmic Solution 0.5%) | 膚積膚構製壓築衊蓋範(願餘夢夢鹹夢鬱製選築) = 衊構糧憲繭衊築廠鬱餘 製糧艱廠齋鹹鏇繭艱願 (鹹艱築願衊膚觸糧鹹繭, 2.673) 更多 | ||||||
临床4期 | 204 | 簾壓憲憲顧選壓餘鑰鹹(鏇鏇繭繭遞襯願願遞蓋) = 襯衊衊憲襯齋鑰膚衊遞 構製窪鑰製鏇鏇網艱鹽 (願繭鹹網醖廠顧範製製, 2.46) 更多 | - | 2011-11-24 | |||
临床3期 | 474 | 繭醖窪蓋構蓋窪鏇糧鬱(襯窪艱蓋膚壓窪衊獵製) = 夢鑰艱繭膚衊網築觸積 蓋範構襯鹽簾範製顧壓 (糧廠窪衊繭醖衊膚齋網 ) | 积极 | 2011-06-01 | |||
timolol | 繭醖窪蓋構蓋窪鏇糧鬱(襯窪艱蓋膚壓窪衊獵製) = 鏇糧壓壓蓋顧齋願鏇襯 蓋範構襯鹽簾範製顧壓 (糧廠窪衊繭醖衊膚齋網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用